Imaging response assessment in oncology Journal Article


Authors: Curran, S. D.; Muellner, A. U.; Schwartz, L. H.
Article Title: Imaging response assessment in oncology
Abstract: The role of imaging in the clinical setting as well as in the drug development process is expanding rapidly. Imaging technology now exists that is capable of detecting tumor response within hours. In parallel with this advance, a new array of more targeted and specific therapies are being developed. This paradigm shift in turn demands a more sophisticated way of quantifying response. There is a need to update and modify the current response evaluation criteria in solid tumors (RECIST), which rely solely on anatomic size measurement of tumors. In addition, response assessment guidelines will need to be increasingly disease-specific. Response assessment by imaging is now intimately involved with all stages of the drug development process, from exploratory drug discovery through clinical trials, as well as in clinical use. Imaging biomarkers and surrogate endpoints have the potential to speed drug approval significantly. The major funding institutions and the pharmaceutical industry are working more and more with researchers to help maintain progress in this multidisciplinary area involving oncologists, radiologists, molecular imaging specialists, medical physicists, and computer scientists. (c) International Cancer Imaging Society.
Keywords: treatment outcome; nuclear magnetic resonance imaging; positron emission tomography; methodology; magnetic resonance imaging; neoplasm; neoplasms; tumor markers, biological; practice guideline; pathology; diagnostic imaging; drug design; oncology; tumor marker; standard; positron-emission tomography; scintiscanning; medical oncology; forecasting; radiography; world health organization; chemical structure; molecular structure; guidelines
Journal Title: Cancer Imaging
Volume: 6
Issue: A
ISSN: 1470-7330
Publisher: Biomed Central Ltd  
Date Published: 2006-01-01
Start Page: S126
End Page: S130
Language: English
DOI: 10.1102/1470-7330.2006.9039
PUBMED: 17114065
PROVIDER: scopus
PMCID: PMC1805076
DOI/URL:
Notes: --- - "Cited By (since 1996): 19" - "Export Date: 4 June 2012" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Sean Curran
    9 Curran
  2. Lawrence H Schwartz
    306 Schwartz